Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. (2016)

Peer-Reviewed Study · Tara Williamson; Ren-Yuan Bai; Verena Staedtke et al. · October 18, 2016

Tara Williamson et al., 2016-10-18: Williamson et al. test mebendazole, sulindac and the combination in the ApcMin/+ mouse model of familial adenomatous polyposis; mebendazole alone cut intestinal adenomas by 56% and the combination by 90%.

Compared with the total number of tumors in the intestine of untreated ApcMin/+ mice (62.5 ± 7.50), 35 mg/kg MBZ continuous dose administered in the feed for 9 weeks significantly reduced the number of tumors by 56% (27.25 ± 2.68, P = 0.0002) as a single agent.

Tara Williamson et al., 2016-10-18: Williamson et al. test mebendazole, sulindac and the combination in the ApcMin/+ mouse model of familial adenomatous polyposis; mebendazole alone cut intestinal adenomas by 56% and the combination by 90%. Study type: ApcMin/+ mouse chemoprevention model plus HT29/SW480 xenografts. N: not stated in the abstract; groups of mice per arm. Country: USA (Johns Hopkins). Dose: 35 mg/kg in feed for 9 weeks (single agent); 50 mg/kg by gavage five days a week in a second arm; sulindac 160 ppm. Funder: not stated in the record. Declared conflicts: 'TW, VS, RB and GJR are inventors on Johns Hopkins patent applications related to a reformulated version of Mebendazole and Mebendazole's use for cancer prevention.' Comparator: untreated ApcMin/+ mice, sulindac alone, and the combination. IMPORTANT NEGATIVE ARM: the 50 mg/kg five-days-a-week gavage schedule 'did not produce a significant outcome (P = 0.1588)' in the same paper. Study type: animal.